InvestorsHub Logo
Followers 0
Posts 1151
Boards Moderated 0
Alias Born 07/10/2003

Re: None

Saturday, 08/14/2004 6:56:03 AM

Saturday, August 14, 2004 6:56:03 AM

Post# of 82595
Do you remember last July's stockholder's meeting ? Do you remember this ? From Tony Not Richard
*************************************************************************************************
Ancestry 3.0 would take about a year to develop, but will require between $750K to $1 million to fund the research. DNAP would like to solicit a partner willing to fund it's development in exchange for a share of downstream revenues.

- Ovanome is about a year from market, and DNAP anticipates marketing through a partner. I asked if Statnome was similarly a year out, and the response surprised me. Tony indicated that Statnome would be marketed sooner and the marketing would be handled by DNAP. Obviously, the company is anticipating a much larger market for the Statin classifers which would make it cost effective to run the samples on the UHT.

************************************************************************************************

I really have to share this because i think there's something odd about the fact that there is so little info. out on Statnome that i cant help wonder if Tony is going to pull a BIG Surprise on everyone with News on either Statnome coming out or Ovanome this year. Tony has said Statnome is really top secret and a very big money maker.And then in the EXECUTIVE SUMMARY OF OVANOME we have this -
***************************************************************************************************
The clinical trial for OVANOME will be finished in early 2004. An application for approval to market, if required, will be submitted to the FDA by mid-2004 and approval obtained by early 2005. DNAP has a patent pending for compositions and methods relating to OVANOME. Sales of the OVANOME products to labs in 2005 will result in income of $4 million. This product launch will create a new, emerging US market of over $16 million. OVANOME is forecast to reach a peak-year sales record of $12 million in year three and hold steady for several years as the classifier test of choice in this market niche.
*******************************************************************************************
I guess i would like to believe that Tony is going to pull a Big surprise on us all this year.To much to wish for i guess.Dont mine me i'm just dreaming.

God Bless